Drug intelligence / Profile preview

GX-G8

Development stage: Discontinued
Lead developer: Genexine

Overview

GX-G8 is a long-acting **glucagon-like peptide 2 receptor agonist** in the form of an Fc-fusion protein, originally developed by Genexine. Its mechanism involves activation of the glucagon-like peptide 2 receptor (GLP-2R), leading to enhanced intestinal growth and improved gastrointestinal function. GX-G8 was investigated primarily for the treatment of **short bowel syndrome** and related digestive or metabolic disorders, but development has been discontinued[1][12].

Other names: Long acting glucagon like peptide 2 Genexine

Targets

GLP2R (Glucagon-like peptide 2 receptor)

Beyond the preview

Go deeper on GX-G8.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GX-G8.

Explore the full profile